|
1. BIOLOGIE
|
|
|
|
|
When cells cycle fast, cancer gets a jumpstart [Yale Cancer Center]
|
|
|
|
|
|
“When a normal cell that divides quickly meets MLL-AF9, this combination creates a monster cell that is stuck in a state of perpetual fast division,” Guo said. “Their more slowly cycling counterparts remain normal and do not display the malignant cancer traits, even in the presence of cancer-causing mutations.”
|
|
|
|
|
|
|
1.4 BIOLOGIE - TECHNOS, MODÈLES
|
|
|
|
2.6 ETIOLOGIE - ENVIRONNEMENT
|
|
|
Roundup suit lawyer accused of $200 million extortion plot [CBS]
|
|
|
|
|
|
Litzenburg threatened to find people who he would advise to sue the companies for exposing them to the chemical, according to the complaint. Litzenburg told the companies lawyers that he would cease searching for potential plantiffs in exchange for a multi-million-dollar consulting agreement, the complaint claims.
|
|
|
|
|
|
|
3.1 PRÉVENTION - TABAC
|
|
|
|
|
3.1.1 PRÉVENTION - TABAC - E-CIGS
|
|
|
|
3.2 PRÉVENTION - OBÉSITÉ
|
|
|
|
4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC
|
|
|
Gastric cancer susceptibility marker discovered [Institut Pasteur]
|
|
|
|
|
|
Scientists demonstrated that gastric inflammatory lesions caused by H. pylori infection were more severe in a mouse model deficient in factor USF1. These results are also supported by clinical findings, since the prognosis is worse for gastric cancer patients with low levels of USF1 combined with low levels of p53.
|
|
|
|
|
|
|
4.12 BIOPSIES LIQUIDES
|
|
|
|
4.2 DÉP., DIAG. & PRONO. - GÉNOME
|
|
|
|
4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS
|
|
|
|
|
FTC Challenges PacBio Acquisition, Says Illumina is a “Monopolist” [Xconomy]
|
|
|
|
|
|
The debate in the UK over the Illumina-PacBio arrangement continues. Earlier this year, the UK’s Competition and Markets Authority (CMA) released provisional findings from its review, in which it posited that such a deal could “harm critically important innovation in the systems created to support DNA sequencing.”
|
|
|
|
|
|
|
|
4.5 DÉP., DIAG. & PRONO. - COLORECTAL
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
|
5.12.6 IMMUNOTHÉRAPIES - AMM
|
|
|
|
5.12.7 IMMUNOTHÉRAPIES - VACCINS
|
|
|
|
5.2 PHARMA
|
|
|
|
|
5.2.1 PHARMA - PARTENARIATS
|
|
|
|
|
5.2.2 PHARMA - FUSIONS & ACQUISITIONS
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA, NICE...
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
|
|
|
|
|
5.4 TRAITEMENTS - ECONOMIE
|
|
|
|
|
5.9 AACR
|
|
|
|
6.1 OBSERVATION
|
|
|
|
6.10.1 POLITIQUES (USA)
|
|
|
|
|
|
|
|
6.6 PUBLICATIONS
|
|
|
|
|
|
6.7.3 DMP
|
|
|
|
6.9 CONTROVERSES
|
|
|